Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin crossover mechanistic kidney function study in participants with or without type 2 diabetes
2020-000165-16Phase 4Active
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of empagliflozin in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD) and hypertension (HTN) (2 arms), sponsored by Amsterdam University Medical Center. Started Mar 2020; status: active.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)hypertension (HTN)
Beyond the preview
Go deeper on 2020-000165-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000165-16.